|
|
Affection of short-term and low-dose glucocorticoid on bone mineral density and bone metabolism in the treatment of male patients with ankylosing spondylitis |
Department of Rheumatism, the People’s Hospital of Fuyang, Hangzhou, 311400
|
|
Cite this article: |
WEN Li,WANG Guoliang,SHENG Tongliang, et al. Affection of short-term and low-dose glucocorticoid on bone mineral density and bone metabolism in the treatment of male patients with ankylosing spondylitis[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(11): 835-.
|
|
Abstract Objective: Explore the change of bone mineral density and bone metabolism in male patients with ankylosing spondylitis by short-term and low-dose glucocorticoid. Methods: Randomly divide 46 patients into non-GC treatment group (22) and low-dose GC treatment group (24). Non-GC treatment group receive DMARD and Ca, Low-dose GC treatment group receive low dose glucocorticoid as well as DMARD and Ca. The Serum levels of osteoprotegerin (OPG), macrophage-colony stimulating factors (M-CSF), erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), bath AS disease activity index (BASDAI) and Bone mineral density (BMD) were measured at the baseline and 6 months after therapy. Results: Six months after treatment, the level of OPG increased significantly (P<0.05) and the level of ESR, CRP, BASDAI decreased significantly (P<0.05) in both groups respectively, compared with that at the baseline; the level of M-CSF of two treatment groups decreased, in which the low-dose GC treatment group did more significantly (P<0.05). Six months after treatment, there was no significant difference in the levels of OPG, M-CSF, and BMD (P<0.05) between the two groups. There was significant difference in the levels of ESR, CRP, BASDAI between the two groups (P>0.05).Conclusion: Short-term treatment of low-dose GC affect bone metabolisms and inflamed index, while with no significant influence on BMD in AS patients. It is safe and benefit for AS patients.
|
Received: 16 December 2013
|
|
|
|
|
|
|
|